Biohaven Ltd
BHVN13.935USD
-0.135-0.96%
종가 09/12, 16:00（ET）시세는 15분 지연됩니다
1.47B시가총액
손실P/E TTM
자세한 내용은 Biohaven Ltd 회사
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.
회사 정보
종목 코드 BHVN
회사 이름Biohaven Ltd
상장일Sep 23, 2022
CEODr. Vlad Coric, M.D.
직원 수256
유형Ordinary Share
회계 연도 종료Sep 23
주소215 Church Street
도시NEW HAVEN
증권 거래소NYSE Consolidated
국가United States of America
우편 번호06510
전화12034040410
웹사이트https://www.biohaven.com/
종목 코드 BHVN
상장일Sep 23, 2022
CEODr. Vlad Coric, M.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Director
Director
22.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Dr. Irina Antonijevic, M.D., Ph.D.
Dr. Irina Antonijevic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Dr. Vlad Coric, M.D.
Dr. Vlad Coric, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Director
Director
22.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, Aug 16
마지막 업데이트: Sat, Aug 16
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
8.72%
1919 Investment Counsel, LLC
6.23%
Childs John W
6.15%
BlackRock Institutional Trust Company, N.A.
6.08%
Suvretta Capital Management, LLC
5.31%
기타
67.49%
주주
주주
비율
The Vanguard Group, Inc.
8.72%
1919 Investment Counsel, LLC
6.23%
Childs John W
6.15%
BlackRock Institutional Trust Company, N.A.
6.08%
Suvretta Capital Management, LLC
5.31%
기타
67.49%
주주 유형
주주
비율
Investment Advisor
34.60%
Investment Advisor/Hedge Fund
25.54%
Hedge Fund
16.34%
Individual Investor
11.13%
Research Firm
3.52%
Venture Capital
1.11%
Sovereign Wealth Fund
0.85%
Corporation
0.48%
Pension Fund
0.47%
기타
5.96%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
561
102.09M
99.98%
-11.50M
2025Q1
573
104.91M
102.74%
-8.33M
2024Q4
560
105.43M
103.87%
-2.30M
2024Q3
544
99.41M
101.90%
-4.10M
2024Q2
514
95.57M
103.25%
+3.60M
2024Q1
494
86.58M
104.39%
-3.45M
2023Q4
444
83.44M
104.38%
+4.72M
2023Q3
398
73.50M
107.61%
-2.29M
2023Q2
372
72.49M
106.13%
-7.40M
2023Q1
331
78.42M
114.97%
+3.79M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
8.40M
8.23%
+4.76K
+0.06%
Mar 31, 2025
1919 Investment Counsel, LLC
6.59M
6.46%
+34.44K
+0.53%
Mar 31, 2025
Childs John W
6.51M
6.38%
+351.58K
+5.71%
Mar 10, 2025
BlackRock Institutional Trust Company, N.A.
6.32M
6.19%
-61.68K
-0.97%
Mar 31, 2025
Suvretta Capital Management, LLC
5.62M
5.5%
--
--
Mar 31, 2025
Janus Henderson Investors
6.44M
6.3%
-544.20K
-7.79%
Mar 31, 2025
State Street Global Advisors (US)
3.42M
3.35%
-90.13K
-2.57%
Mar 31, 2025
Coric (Vladimir)
3.18M
3.11%
+26.57K
+0.84%
Mar 10, 2025
T. Rowe Price Associates, Inc.
2.74M
2.69%
-594.84K
-17.82%
Mar 31, 2025
Bellevue Asset Management AG
2.04M
2%
--
--
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Sep 6
마지막 업데이트: Sat, Sep 6
이름
비율
iShares Neuroscience and Healthcare ETF
3.16%
Roundhill GLP-1 & Weight Loss ETF
1.85%
Global X Guru Index ETF
1.14%
Virtus LifeSci Biotech Clinical Trials ETF
0.81%
F/m Emerald Life Sciences Innovation ETF
0.61%
Inspire Small/Mid Cap ESG ETF
0.22%
JPMorgan Fundamental Data Science Small Core ETF
0.19%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.09%
BNY Mellon US Small Cap Core Equity ETF
0.07%
Strive Small-Cap ETF
0.05%
더 보기
iShares Neuroscience and Healthcare ETF
비율3.16%
Roundhill GLP-1 & Weight Loss ETF
비율1.85%
Global X Guru Index ETF
비율1.14%
Virtus LifeSci Biotech Clinical Trials ETF
비율0.81%
F/m Emerald Life Sciences Innovation ETF
비율0.61%
Inspire Small/Mid Cap ESG ETF
비율0.22%
JPMorgan Fundamental Data Science Small Core ETF
비율0.19%
JPMorgan BetaBuilders US Small Cap Equity ETF
비율0.09%
BNY Mellon US Small Cap Core Equity ETF
비율0.07%
Strive Small-Cap ETF
비율0.05%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
